Lipid-lowering therapy for prevention of ventricular tachyarrhythmias

Journal of the American College of Cardiology

Volumn 42, Issue 1, 2003, Pages 88-92

  Anderson, Kelley P ^a  

^a MARSHFIELD CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID; CALCIUM; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; OMEGA 3 FATTY ACID; PHOSPHOLIPID; PLACEBO; PRAVASTATIN; PROBUCOL; SIMVASTATIN; SOTALOL;

ANTIARRHYTHMIC ACTIVITY; ANXIETY DISORDER; CELL ASSAY; CELL MEMBRANE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEFIBRILLATION; DEFIBRILLATOR; DISEASE ASSOCIATION; DISEASE MODEL; DOG; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGY; ELECTROSTIMULATION; EPIDEMIC; EXERCISE TEST; HEART ARRHYTHMIA; HEART DEATH; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE TACHYCARDIA; HEMOSTASIS; HUMAN; INCIDENCE; INFLAMMATION; ION CURRENT; ISCHEMIA; ISCHEMIC HEART DISEASE; MEDICAL LITERATURE; MEDICAL RESEARCH; MORTALITY; MUSCLE CELL; NEUROENDOCRINE SYSTEM; NOTE; PAIN; PREDICTION; PRIORITY JOURNAL; RABBIT; RECURRENT DISEASE; RISK ASSESSMENT; SCANDINAVIA; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SUDDEN DEATH; SYNCOPE;

EID: 0037530458     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(03)00497-2     Document Type: Editorial

References (30)

1. Mitchell LB, Powell JL, Gillis AM, Kehl V, Hallstrom AP, and the AVID Investigators. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol 2003;42:81-7.
2. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-83.
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
4. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
5. Pratt CM, Waldo AL, Camm AJ. Can antiarrhythmic drugs survive survival trials? Am J Cardiol 1998;81:24D-34D.
6. Exner DV, Reiffel JA, Epstein AE, et al. Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol 1999;34:325-33.
7. Sears SF Jr, Todaro JF, Lewis TS, Sotile W, Conti JB. Examining the psychosocial impact of implantable cardioverter defibrillators: a literature review. Clin Cardiol 1999;22:481-9.
8. Pacifico A, Hohnloser SH, Williams JH, et al. Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. N Engl J Med 1999;340:1855-62.
9. van Boven AJ, Jukema JW, Zwinderman AH, Crijns HJ, Lie KI, Bruschke AV. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group. Circulation 1996;94:1503-5.
10. Shusterman V, Aysin B, Gottipaty V, et al. Autonomic nervous system activity and the spontaneous initiation of ventricular tachycardia. J Am Coll Cardiol 1998;33:1891-9.
11. Gioia G, Bagheri B, Gottlieb CD, et al. Prediction of outcome of patients with life-threatening ventricular arrhythmias treated with automatic implantable cardioverter-defibrillators using SPECT perfusion imaging. Circulation 1997;95:390-4.
12. Brugada J, Aguinaga L, Mont L, Betriu A, Mulet J, Sanz G. Coronary artery revascularization in patients with sustained ventricular arrhythmias in the chronic phase of a myocardial infarction: effects on the electrophysiologic substrate and outcome. J Am Coll Cardiol 2001;37:529-33.
13. The AVID Investigators. Antiarrhythmics Versus Implantable Deftbrillators (AVID) - rationale, design, and methods. Am J Cardiol 1995;75:470-5.
14. Causes of death in the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol 1999;34:1552-9.
15. Anderson KP, Walker R, Dustman T, Fuller M, Mori M. Spontaneous sustained ventricular tachycardia in the Electrophyslologic Study Versus Electrocardiographic Monitoring (ESVEM) trial. J Am Coll Cardiol 1995;26:489-96.
16. Anderson KP. Sympathetic nervous system activity and ventricular tachyarrhythmias: recent advances. Ann Noninvasive Electrocardiol 2003;8:75-89.
17. Pehlivanidis AN, Athyros VG, Demitriadis DS, Papageorgiou AA, Bouloukos VJ, Kontopoulos AG. Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease. Atherosclerosis 2001;157:463-9.
18. Lamers JM, Hartog JM, Verdouw PD, Hulsmann WC. Dietary fatty acids and myocardial function. Basic Res Cardiol 1987;82 Suppl 1:209-21.
19. Leaf A, Xiao YF. The modulation of ionic currents in excitable tissues by n-3 polyunsaturated fatty acids. J Membr Biol 2001;184:263-71.
20. Honen BN, Saint DA. Polyunsaturated dietary fats change the properties of calcium sparks in adult rat atrial myocytes. J Nutr Biochem 2002;13:322-9.
21. Katz AM. Trans-fatty acids and sudden cardiac death. Circulation 2002;105:669-71.
22. Hayashidani S, Tsutsui H, Shiomi T, et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002;105:868-73.
23. Patel R, Nagueh SF, Tsybouleva N, et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001;104:317-24.
24. Nakamura R, Egashira K, Machida Y, et al. Probucol attenuates left ventricular dysfunction and remodeling in tachycardia-induced heart failure - roles of oxidative stress and inflammation. Circulation 2002;106:362-7.
25. Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction - time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza neU'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002;105:1897-903.
26. Bigger JT Jr, El-Sherif T. Polyunsaturated fatty acids and cardiovascular events: a fish tale. Circulation 2001;103:623-5.
27. De Sutter J, Tavernier R, De Buyzere M, Jordaens L, De Backer G. Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. J Am Coll Cardiol 2000;36:766-72.
28. Anderson KP, Schloss EJ. ESVEM tells us what we don't know. Circulation 1995;92:3144.
29. Newby LK, Kristinsson A, Bhapkar MV, et al. Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA 2002;287:3087-95.
30. De Sutter J, Firsovaite V, Tavernier R. Prevention of sudden death in patients with coronary artery disease: do lipid-lowering drugs play a role? Prev Cardiol 2002;5:177-82.